98-6891. Government-Owned Inventions; Availability for Licensing

[Federal Register Volume 63, Number 51 (Tuesday, March 17, 1998)]
[Notices]
[Page 13058]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-6891]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: [phone]; fax: [phone]. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

A Novel Adipose Seven Transmembrane Domain Protein

C Montrose-Rafizad, H Yang (NIA)

OTT Reference No. E-213-97/0 filed 19 Jun 97

Licensing Contact: Stephen Finley, 301/496-7056, ext. 215

    A new seven transmembrane protein and cDNA clone has been isolated 
from mouse adipose tissues. The new clone is differentially expressed 
in several mouse and human tissues, but is overexpressed in the 
epididymal tissues of diabetic mice and in the epididymal tissues of 
older mice. It is thought this new clone may have important 
implications in aging and diabetes and may be helpful for studying 
aging and diabetes.

Human Papilloma Virus Inhibition by Anti-Sense Oligonucleotides

JA DiPaolo, L Alvarez-Salas (NCI)

Serial No. 08/929,140 filed 05 Sep 97

Licensing Contact: Carol Salata, 301/496-7735, ext. 232

    The present invention relates to the use of antisense 
oligonucleotides to inhibit a Human Papilloma virus (HPV). The 
invention derives from the observation that an inhibited ribozyme, 
which bound to a specific sequence of the HPV16 E6 gene, but whose 
cutting ability had been destroyed, still inhibited HPV16. This leads 
to the conclusion that antisense molecules which bind to the same 
section of the E6 gene would be useful in the treatment of HPV 
infection. The antisense molecules have the advantage of being less 
expensive to manufacture than ribozymes. The antisense oligonucleotides 
have phosphorothioate backbone structure and sequences complimentary to 
portions of human papilloma virus 16.

    Dated: March 7, 1998.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 98-6891 Filed 3-16-98; 8:45 am]
BILLING CODE 4140-01-M